In IgA Nephropathy and FSGS
Proteinuria Could Be Putting Your Patients at High Risk
Proteinuria is a key prognostic indicator of progression in both IgA nephropathy and FSGS1-8
Proteinuria perpetuates a cycle of kidney fibrosis, as proximal tubular reabsorption of excess protein contributes to tubulointerstitial injury5,7,8
Reduction in proteinuria results in a decrease in glomerular pressure and reduction of podocyte damage.1
Lower proteinuria levels are critical to preserving kidney function1,9,10
TARGETED PROTEINURIA GOALS1,3
aFSGS partial remission threshold defined as <1.5 g/g with a 40% reduction from baseline.
Evidence-based thresholds translate to clinically meaningful treatment goals
Despite receiving standard-of-care treatment, many patients face a poor prognosis due to elevated proteinuria levels, making the need for novel medications urgent.1
Explore the role of ET-1 and Ang II
Ang II=angiotensin II; ET-1=endothelin-1; FSGS=focal segmental glomerulosclerosis; IgA=immunoglobulin A.
References:
1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276. 2. Troyanov S, et al. J Am Soc Nephrol. 2005;16:1061-1068. 3. Inker LA, et al. Am J Kidney Dis. 2016:1-10. 4. D’Agati VD, et al. New Engl J Med. 2011;365:2398-2411. 5. Remuzzi G, et al. New Engl J Med. 1998;339:1448-1456. 6. Ruggenenti P, et al. Kidney Int. 1998;53:1209-1216. 7. Dhaun N, et al. Br J Pharmacol. 2012;167:720-731. 8. Cravedi P, et al. Br J Clin Pharmacol. 2013;76(4):516-523. 9. Troost JP, et al. Am J Kidney Dis. 2021;77:216-225. 10. Troost JP, et al. Clin J Am Soc Nephrol. 2018;13:414-421. 11. Komers R, et al. Am J Physiol Regul Integr Comp Physiol. 2016:R877-R884. 12. Kohan DE, et al. Kidney Int. 2014;86:896-904. 13. Raina R, et al. Kidney Dis. 2020;6:22-34.